Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced ...

A new study used pathway-level blood metabolomics to identify lifestyle-associated metabolic patterns linked to physical, cognitive, and daily functional performance across CN, MCI, and AD. The ...

A new review was published in Volume 18 of Aging on May 30, 2026, titled "The love and hate relationship between cellular ...

The FDA has granted Fast Track designation to BM-3103, a novel topical mTOR inhibitor for epidermolysis bullosa simplex currently in phase 2.